Bristol-Myers Squibb (BMY) Tops Q2 EPS by 1c; Raises FY11 Outlook
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $64.69 -3.19%
Revenue Growth %: +3.2%
Financial Fact:
Net Earnings Attributable to Noncontrolling Interest: 13M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +3.2%
Financial Fact:
Net Earnings Attributable to Noncontrolling Interest: 13M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Bristol-Myers Squibb Company (NYSE: BMY) reported Q2 EPS of $0.56, $0.01 better than the analyst estimate of $0.55. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.04 billion.
Sees FY2011 EPS of $2.20-$2.30, versus prior guidance of $2.10-$2.20 and the consensus of $2.21.
Sees FY2011 EPS of $2.20-$2.30, versus prior guidance of $2.10-$2.20 and the consensus of $2.21.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
- UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
